Secondary progressive multiple sclerosis: current knowledge and future challenges.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Lancet Neurology

• Publication date

  2006-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1474-4422(06)70410-0PMID 16545751
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Perforation of the infracted interventricular septum diagnosed ante mortem.

  2009cited by this paper
• The natural history of multiple sclerosis

  2006cited by this paper
• Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter.

  2006cited by this paper
• Increased disability and MRI lesions after discontinuation of IFN‐β‐1a in secondary progressive MS

  2005cited by this paper
• Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI

  2005cited by this paper
• MR spectroscopic evidence for glial increase but not for neuro‐axonal damage in MS normal‐appearing white matter

  2005cited by this paper
• Cortical demyelination and diffuse white matter injury in multiple sclerosis.

  2005cited by this paper
• Diffusion MRI in multiple sclerosis

  2005cited by this paper
• Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype.

  2005cited by this paper
• Placebo-controlled multicentre randomised trial of interferon (cid:1) -1b in treatment of secondary progressive multiple sclerosis

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis

  2005cited by this paper
• Effect of mitoxantrone on MRI in progressive MS

  2005cited by this paper
• Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients

  2005cited by this paper
• Immunological patterns identifying disease course and evolution in multiple sclerosis patients.

  2005cited by this paper
• McAlpine's Multiple Sclerosis

  2005cited by this paper
• Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.

  2005cited by this paper
• Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes.

  2005cited by this paper
• The window of therapeutic opportunity in multiple sclerosis

  2005cited by this paper
• MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS)

  2005cited by this paper
• Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients

  2005cited by this paper
• Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain

  2004cited by this paper
• Interferon beta-1b in secondary progressive MS

  2004cited by this paper
• Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta

  2004cited by this paper
• Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

  2004cited by this paper
• Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation

  2004cited by this paper
• Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis

  2004cited by this paper
• Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis.

  2004cited by this paper
• The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results.

  2004cited by this paper
• Interferon beta-1b in secondary progressive MS

  2004cited by this paper
• Magnetisation transfer ratio: a robust measure of myelin content in post-mortem multiple sclerosis brain

  2004cited by this paper
• Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis

  2003cited by this paper
• MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

  2003cited by this paper
• Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis

  2003cited by this paper
• Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis.

  2003cited by this paper
• Primary and secondary progressive multiple sclerosis.

  2003cited by this paper
• A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis

  2003cited by this paper
• Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon β-1a (Rebif) treatment trial

  2003cited by this paper
• Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis.

  2003cited by this paper
• The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS

  2003cited by this paper
• Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis

  2003cited by this paper
• Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

  2003cited by this paper
• Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.

  2003cited by this paper
• Cortical motor reorganization after a single clinical attack of multiple sclerosis.

  2002cited by this paper
• Magnetization Transfer Ratio Histogram Analysis of Normal-Appearing Gray Matter and Normal-Appearing White Matter in Multiple Sclerosis

  2002cited by this paper
• Benefit of interferon &bgr;-1a on MSFC progression in secondary progressive MS

  2002cited by this paper
• Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.

  2002cited by this paper
• Intravenous immunoglobulin G for the treatment of relapsing–remitting multiple sclerosis: a meta‐analysis

  2002cited by this paper
• Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

  2002cited by this paper
• Intra-voxel and inter-voxel coherence in patients with multiple sclerosis assessed using diffusion tensor MRI

  2002cited by this paper
• Evidence for widespread movement-associated functional MRI changes in patients with PPMS

  2002cited by this paper
• Correlations between Structural CNS Damage and Functional MRI Changes in Primary Progressive MS

  2002cited by this paper
• Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study.

  2002cited by this paper
• Hematopoietic stem cell transplantation for multiple sclerosis

  2002cited by this paper
• Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.

  2002cited by this paper
• Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging.

  2002cited by this paper
• Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis

  2001cited by this paper
• Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.

  2001cited by this paper
• Diffusion tensor magnetic resonance imaging in multiple sclerosis

  2001cited by this paper
• Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy.

  2001cited by this paper
• Magnetic Resonance Spectroscopy in Multiple Sclerosis

  2001cited by this paper
• Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations

  2001cited by this paper
• Optimizing the association between disability and biological markers in MS

  2001cited by this paper
• Ring-enhancement in multiple sclerosis: marker of disease severity

  2001cited by this paper
• Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS

  2001cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• Interferon-β1b in the treatment of secondary progressive MS

  2001cited by this paper
• Distinct chemokine receptor and cytokine expression profile in secondary progressive MS

  2001cited by this paper
• CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis.

  2001cited by this paper
• Randomized controlled trial of interferon- beta-1a in secondary progressive MS

  2001cited by this paper
• Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.

  2001cited by this paper
• In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis.

  2001cited by this paper
• Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

  2001cited by this paper
• T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.

  2001cited by this paper
• Randomized controlled trial of interferon-beta-1a in secondary progressive MS

  2001cited by this paper
• Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS

  2001cited by this paper
• Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis.

  2001cited by this paper
• Immunopathology of secondary‐progressive multiple sclerosis

  2001cited by this paper
• Inflammation and atrophy in multiple sclerosis: MRI associations with disease course.

  2001cited by this paper
• Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS

  2001cited by this paper
• Erratum: Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy (Journal of the Neurological Sciences 184 (2001) (155-162) PII: S0022510X01004312)

  2001cited by this paper
• Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension

  2001cited by this paper
• The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

  2000cited by this paper
• Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis.

  2000cited by this paper
• Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.

  2000cited by this paper
• A magnetization transfer histogram study of normal-appearing brain tissue in MS

  2000cited by this paper
• Magnetization transfer imaging to monitor the evolution of MS

  2000cited by this paper
• Whole-brain diffusion MR histograms differ between MS subtypes

  2000cited by this paper
• A prospective study on the prognosis of multiple sclerosis

  2000cited by this paper
• A conventional and magnetization transfer MRI study of the cervical cord in patients with MS

  2000cited by this paper
• Whole brain volume changes in patients with progressive MS treated with cladribine

  2000cited by this paper
• Cladribine and progressive MS

  2000cited by this paper
• Linomide in relapsing and secondary progressive MS

  2000cited by this paper
• Relapses and progression of disability in multiple sclerosis.

  2000cited by this paper
• The effect of cladribine on T(1) 'black hole' changes in progressive MS.

  2000cited by this paper
• Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis

  2000cited by this paper
• Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H

  1999cited by this paper
• Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis

  1999cited by this paper
• Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability

  1999cited by this paper
• Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients.

  1999cited by this paper

• Plasmaphosphorylated tau as biomarkers for multiple sclerosis diagnosis, subtyping, and prognosis

  2026cites this paper
• Personalized Treatment Response in Progressive MS: Can the Patient's Profile Influence the Outcome?

  2025cites this paper
• The Role of M6A Modification in Autoimmunity: Emerging Mechanisms and Therapeutic Implications

  2025cites this paper
• Advances in the understanding and management of multiple sclerosis phenotypes

  2025cites this paper
• Mathematical Modelling of Disability Progression in Patients with Multiple Sclerosis

  2025cites this paper
• Longitudinal analysis of cerebellum volume changes in a multiple sclerosis cohort

  2025cites this paper
• Plasma phosphorylated tau 181 and 217 as biomarkers for multiple sclerosis diagnosis, subtyping, and prognosis

  2025cites this paper
• Impact of kynurenine metabolites on B and T cells in multiple sclerosis and allergies

  2025cites this paper
• Cellular Senescence in Glial Cells: Implications for Multiple Sclerosis

  2025cites this paper
• Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair

  2024cites this paper
• Measuring Disease Progression in Multiple Sclerosis Clinical Drug Trials and Impact on Future Patient Care

  2024cites this paper
• An update on managing patients with multiple sclerosis in primary care

  2024cites this paper
• Astrocyte Activation and Drug Target in Pathophysiology of Multiple Sclerosis.

  2024cites this paper
• Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis.

  2024cites this paper
• Unveiling the fate and potential neuroprotective role of neural stem/progenitor cells in multiple sclerosis

  2024cites this paper
• Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?

  2024cites this paper
• Evaluation of the quality and the productivity of neuroradiological reading of multiple sclerosis follow-up MRI scans using an intelligent automation software

  2024cites this paper
• Clinical characteristics and dynamics of disability progression in a cohort of patients with multiple sclerosis in Latvians

  2024cites this paper
• Association of the Cervical Canal Area With Disability and Progression in People With Multiple Sclerosis

  2024cites this paper
• On the effect of remyelination in a mathematical model of multiple sclerosis

  2023cites this paper
• The immunomodulatory effects of all-trans retinoic acid and docosahexaenoic acid combination treatment on the expression of IL-2, IL-4, T-bet, and GATA3 genes in PBMCs of multiple sclerosis patients

  2023influential citation
• Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

  2023cites this paper
• Medication persistence among people with multiple sclerosis in Slovenia treated with dimethyl fumarate

  2023cites this paper
• Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trials

  2023cites this paper
• Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study

  2023cites this paper
• Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis: What Is the Future of Multiple Sclerosis Treatment?

  2023cites this paper
• Task-oriented exercise effects on walking and corticospinal excitability in multiple sclerosis: protocol for a randomized controlled trial

  2023cites this paper
• Patient-reported outcomes in multiple sclerosis: a prospective registry cohort study

  2023cites this paper
• Immune-mediated neurodegenerative trait provoked by multimodal derepression of long-interspersed nuclear element-1

  2022cites this paper
• Role of the Bruton tyrosine kinase pathway in multiple sclerosis.

  2022cites this paper
• The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis

  2022cites this paper
• Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.

  2022cites this paper
• [The first russian experience of use of siponimod in real clinical practice].

  2022cites this paper
• Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study

  2022cites this paper
• Proteomics in Multiple Sclerosis: The Perspective of the Clinician

  2022cites this paper
• Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD

  2022cites this paper
• Improved Detection, Description and Efficiency of Multiple Sclerosis Neuroradiological Lesions' Assessment using a Semi-Automatic Dedicated Deep-Learning Based Software Jazz

  2022cites this paper
• Targeted Delivery Platforms for the Treatment of Multiple Sclerosis.

  2022cites this paper
• Diagnosis and treatment of progressive multiple sclerosis: A position paper

  2022cites this paper
• Role of lipoic acid in multiple sclerosis

  2021cites this paper
• Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.

  2021cites this paper
• Texture Analysis and Its Applications in Biomedical Imaging: A Survey

  2021cites this paper
• N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis

  2021influential citation
• Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.

  2021cites this paper
• Self-efficacy training as an adjunct to exercise in a person with progressive multiple sclerosis: a case report

  2021cites this paper
• Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis

  2021cites this paper
• Experiences of Relapsing Remitting Multiple Sclerosis and Disease Modifying Treatment: A phenomenological inquiry

  2021cites this paper
• The Distribution of GPR17-Expressing Cells Correlates with White Matter Inflammation Status in Brain Tissues of Multiple Sclerosis Patients

  2021cites this paper
• Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of multiple sclerosis

  2021cites this paper
• Organic dots (O-dots) for theranostic applications: preparation and surface engineering

  2021cites this paper
• Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.

  2021cites this paper
• Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis

  2020cites this paper
• Early Diagnosis of Multiple Sclerosis Based on Optical and Electrochemical Biosensors: Comprehensive Perspective

  2020cites this paper
• Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

  2020cites this paper
• Secondary progressive multiple sclerosis - from neuropathology to definition and effective treatment.

  2020cites this paper
• Microglia as therapeutic target in central nervous system disorders.

  2020cites this paper
• Sensorimotor function in progressive multiple sclerosis

  2020influential citation
• Siponimod and Cognition in Secondary Progressive Multiple Sclerosis

  2020cites this paper
• Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial

  2020cites this paper
• Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis

  2020cites this paper
• Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM)

  2020cites this paper
• Epstein-Barr Virus Infection in the Development of Neurological Disorders.

  2020cites this paper
• The Role of Interleukin-6 as an Indicator of Multiple Sclerosis Progression From Relapse Remitting to Sec- ondary Progressive Status

  2020cites this paper
• Using measures of corticospinal excitability to map symptom severity in multiple sclerosis

  2020cites this paper
• EVALUATION OF NOVEL RADIOPHARMACEUTICALS FOR POSITRON EMISSION TOMOGRAPHY IMAGING OF ANIMAL MODELS OF MULTIPLE SCLEROSIS

  2020cites this paper
• Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis

  2020cites this paper
• Stereological Investigation of Regional Brain Volumes after Acute and Chronic Cuprizone-Induced Demyelination

  2019cites this paper
• YKL-40 IS A CSF BIOMARKER OF INTRATHECAL INFLAMMATION IN SECONDARY

  2019cites this paper
• Cognitive speed and white matter integrity in secondary progressive multiple sclerosis.

  2019cites this paper
• Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets

  2019cites this paper
• Ultrasound investigation of risk factors for extracranial vascular pathology in patients with multiple sclerosis

  2019cites this paper
• Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany

  2019cites this paper
• Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS

  2019cites this paper
• Behavioural phenotypes in the cuprizone model of central nervous system demyelination.

  2019cites this paper
• Risk of secondary progressive multiple sclerosis: A longitudinal study

  2019cites this paper
• Impact of natural menopause on multiple sclerosis: a multicentre study

  2019cites this paper
• Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients

  2019cites this paper
• T cells are altered in secondary progressive multiple sclerosis

  2019influential citation
• Eficàcia de l’exercici físic i terapèutic com a tractament en la marxa de pacients adults amb esclerosis múltiple. Una revisió sistemàtica

  2019cites this paper
• Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis

  2019cites this paper
• Coexistence of Multiple Sclerosis and Alzheimer's disease: A review.

  2019cites this paper
• Microglia suppress the secondary progression of autoimmune encephalomyelitis

  2019cites this paper
• A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT.

  2019cites this paper
• CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease

  2019cites this paper
• A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.

  2019cites this paper
• Schwanger und krank — was ist zu tun?

  2019cites this paper
• Short-term prediction of secondary progression in a sliding window: A test of a predicting algorithm in a validation cohort

  2019cites this paper
• Clinical relevance of brain atrophy measures in multiple sclerosis

  2019cites this paper
• Socioeconomic status and disability progression in multiple sclerosis

  2019cites this paper
• Effect of risk propensity on treatment understanding and decisions in MS patients

  2019cites this paper
• When an octopus has MS: Application of neurophysiology and immunology of octopuses for multiple sclerosis.

  2019cites this paper
• Secondary-Progressive Multiple Sclerosis

  2018cites this paper
• Clinical Course of Multiple Sclerosis.

  2018cites this paper
• The role of optical coherence tomography and infrared oculography in assessing the visual pathway and central nervous system in Multiple Sclerosis

  2018cites this paper
• The Role of High‐Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis

  2018cites this paper
• Inhibiting repulsive guidance molecule-a suppresses secondary progression in mouse models of multiple sclerosis

  2018cites this paper
• A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis

  2018cites this paper
• The neural correlates of effort-related and effort-unrelated fatigue in patients with multiple sclerosis

  2018cites this paper
• Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches

  2018cites this paper
• The role of optical coherence tomography and infrared oculography in assessing the visual pathway and CNS in multiple sclerosis.

  2018cites this paper